RECRUITING

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.

Official Title

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

Quick Facts

Study Start:2023-09-12
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05761860

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:45 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals fluent in English will participate.
  2. * Must report some experience with opioids (e.g., oxycodone, defined as use at least once in the subject's lifetime).
  3. * Be within 20% of their ideal body weight.
  4. * Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  5. * Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  6. * Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.
  1. * Significant current physical disease or major (uncontrolled) psychiatric disorder.
  2. * No self-reported current interest in drug abuse treatment.
  3. * Women who are pregnant or nursing.
  4. * Any severe comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.

Contacts and Locations

Study Contact

Lauren E Nieder, MSPH
CONTACT
(352) 294-1067
lauren.nieder@ufl.edu

Principal Investigator

Meredith S Berry, PhD
PRINCIPAL_INVESTIGATOR
University of Florida

Study Locations (Sites)

University of Florida
Gainesville, Florida, 32611
United States

Collaborators and Investigators

Sponsor: University of Florida

  • Meredith S Berry, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-12
Study Completion Date2025-09

Study Record Updates

Study Start Date2023-09-12
Study Completion Date2025-09

Terms related to this study

Keywords Provided by Researchers

  • Pain
  • Abuse liability

Additional Relevant MeSH Terms

  • Pain